NeuroSense Therapeutics receives delisting notice from Nasdaq due to insufficient equity.

NeuroSense Therapeutics Ltd., a company working on treatments for severe neurodegenerative diseases, received a notice of delisting from Nasdaq due to not meeting the minimum $2.5M stockholders' equity requirement. The company plans to request a hearing before a Nasdaq Hearings Panel to challenge the delisting decision. A successful hearing request would temporarily halt any suspension or delisting actions.

June 21, 2024
3 Articles

Further Reading